A new Centre for Eye Research Australia/ Access Economics report shows the cost of glaucoma will more than double in the next two decades.'Tunnel Vision: the Economic Impact of Primary Open Angle Glaucoma', shows associated healthcare costs totaled $1.9 billion in 2005 and costs are expected to climb to $4.3 billion per annum by 2025, if no changes are made to current practices.
First Insight(R) And DrFirst(R) Launch A True "End-to-End" E-Prescribing Solution For The Ophthalmic Industry
First Insight Corporation, a leading practice management and electronic medical records (EMR) software company, and DrFirst, the leader in electronic prescribing and medication reconciliation, announced that First Insight is the first practice management and EMR software company focused exclusive
Inotek begins enrollment for phase 1 trial of IOP-lowering drug
BEVERLY, Mass. Inotek Pharmaceuticals has begun enrolling patients in a phase 1 clinical trial evaluating the safety, tolerability and IOP-lowering potential of INO-8875, a selective adenosine-1 agonist for treating glaucoma, the company announced in a press release.